GlassScriptPhysician profile
Rena D Callahan
NPI 1487856779
$657,957.71
in general payments reported to CMS, 2019-2025
18 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $22K · 2021: $51K · 2022: $120K · 2023: $205K · 2024: $114K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $323K · Travel and Lodging: $47K · Consulting Fee: $45K · Food and Beverage: $9,605 · Honoraria: $1,113 · Grant: $350 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $323,320.00 |
| Travel and Lodging | $47,382.57 |
| Consulting Fee | $44,810.00 |
| Food and Beverage | $9,604.59 |
| Honoraria | $1,112.93 |
| Grant | $350.00 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $247,154.34 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $117,905.19 | 2022-2025 | Orserdu |
| Pfizer INC. | $110,312.82 | 2019-2025 | |
| Seagen INC. | $70,668.47 | 2020-2023 | Tukysa |
| Lilly USA, LLC | $42,183.83 | 2022-2024 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $34,663.22 | 2023-2025 | Enhertu, Datroway |
| Daiichi Sankyo INC. | $18,004.97 | 2022-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $8,131.06 | 2022-2025 | |
| Pfizer International LLC | $4,000.00 | 2020 | |
| Immunomedics, INC. | $2,250.00 | 2020 | |
| F. Hoffmann-La Roche Ag | $1,435.00 | 2025 | |
| Genentech USA, INC. | $577.81 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $250.00 | 2022 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Puma Biotechnology, INC. | $166.09 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2022 | |
| Beigene USA, INC. | $22.16 | 2023 | Brukinsa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.